Laidlaw Capital Markets is pleased to Co-Manage Aldeyra Therapeutics $125,000,000 financing alongside Jefferies and SVB Leerink. Over $300 million raised together since 2014, helping fuel Aldeyra’s excellent execution in developing its pipeline and delivering results for patients and investors.
Read Article: Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
© 2024 Copyright Laidlaw & Company (UK) Ltd. – All Rights Reserved. Laidlaw & Company (UK) Ltd., a FINRA broker-dealer registered in the United States, clears on a fully-disclosed basis through StoneX, a member of the Securities Investor Protection Corporation (SIPC). Laidlaw & Company International Limited is authorized and regulated by the Financial Conduct Authority (FCA) in the UK (Firm Reference No: 537165).
© Copyright 2021 Laidlaw & Company (UK) Ltd. - All Rights Reserved. Laidlaw & Company (UK) Ltd., a FINRA broker-dealer registered in the United States, clears on a fully-disclosed basis through INTL FCStone Financial Inc., a member of the Securities Investor Protection Corporation (SIPC). Laidlaw & Company International Limited is authorized and regulated by the Financial Conduct Authority (FCA) in the UK (Firm Reference No: 537165).
Stay In Touch